



2025 SNMMI annual meeting highlights

Designed to share the latest scientific findings and foster collaboration within the global community, the Annual Meeting of the Society of Nuclear Medicine and Molecular Imaging convened in New Orleans, Louisiana, USA, and welcomed more than 6,000 in-person attendees.

By Catherine Marcic Joyce

Held in the historical and culturally rich city of New Orleans, the 2025 Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting convened at the New Orleans Ernest N. Morial Convention Center beginning June 21. Held each spring and recognized as a global forum for educational, scientific, and networking opportunities in nuclear medicine and molecular imaging, this four-day event attracted a diverse community of professionals and industry leaders and engaged in a comprehensive program designed to share the latest scientific findings and foster collaboration.

This year, the meeting welcomed 6,077 in-person attendees, surpassing the numbers from the 2024 conference in Toronto, Canada. In addition to the in-person presence, there were 1,691 virtual participants, reflecting the event's commitment to accessibility and global engagement.

The theme for the 2025 meeting, "Accelerating the Cure," set the tone for sessions focused on the latest research, practical clinical applications, and the future of nuclear medicine and molecular imaging. Siemens Healthineers was honored

to sponsor the Science Pavilion at this year's meeting.

2025 SNMMI image of the year

A highlight of the conference was the announcement of the 2025 SNMMI Henry N. Wagner, Jr., Image of the Year. Each year, SNMMI selects an image that exemplifies the most promising advances in nuclear medicine and molecular imaging. For 2025, research presented at this year's meeting led to the selection of a grouping of images showing ultra-high-resolution PET images of the brain.¹

Siemens Healthineers features their latest innovations

The conference also featured 2,660 exhibitors, highlighting the latest innovations and services in the field. In addition to celebrating 25 years of innovation in molecular imaging with Biograph PET/CT, Siemens Healthineers captured attention by showcasing their latest advancements. Notable highlights included Biograph Trinion PET/CT, Biograph Vision Quadra total-body PET/CT, the new BIOGRAPH One*

PET/MR, and Symbia Pro.specta SPECT/CT theranostics edition. Attendees were also introduced to PETNET Solutions, Inc, a Siemens Healthineers Company's, expansive global PET radiopharmaceuticals network, underscoring the growing connectivity and innovation within the industry.

An exciting addition to the Siemens Healthineers exhibit this year was a podcast booth that interviewed and recorded guests live on topics ranging from Alzheimer's disease to theranostics. These recordings will be available as playlists on YouTube and Siemens Healthineers Molecular Imaging website.


Comprehensive solutions for Alzheimer's disease and theranostics were key themes woven throughout the booth. Visitors were able to immerse themselves in a virtual reality experience taking them through a theranostics center of excellence. A clinical pathway experience explored the critical roles PET/CT, SPECT/CT, and digital oncology management solutions have in the patient journey. Additionally, interactive clinical pathway experiences highlighted the patient journey and the growing impact of theranostics in the treatment



Bamford begins the luncheon symposium with a presentation on Symbia Pro.specta SPECT/CT for theranostics.



Korsholm presents on her work with BIOGRAPH One PET/MR and Biograph Vision Quadra PET/CT.



New this year were live audio recordings with molecular imaging experts at the Siemens Healthineers booth.

of neuroendocrine tumors (NETs) and prostate cancer. The oncology management solution ARIA CORE for theranostics was also represented.

On Monday, a Meet the Expert presentation was held at the booth. Prof. Dr. Flemming Andersen from Rigshospitalet in Copenhagen, Denmark, introduced BIOGRAPH One PET/MR and was available to discuss his experience with attendees.

Externally, participants attended an external Biograph Vision Quadra user networking event on Sunday evening at an offsite location. This session featured a panel of global users, providing valuable insights and sharing experiences with advanced PET/CT technology.

Innovative technology strategies for transforming imaging services

Every year, industry groups host a multitude of satellite symposia during the annual meeting. On Monday, Siemens Healthineers sponsored a satellite luncheon symposium. The theme of the symposium was “Innovative Technology Strategies for Transforming Imaging Services.” More than 130 attendees listened as guest speaker Toni E. Bamford, CNMT, NMTCB(RS), NCT, ARRT(CT), lead nuclear medicine technologist from PeaceHealth Sacred Heart Medical Center in River Bend in Springfield,

Oregon, USA, presented on advancing clinical SPECT/CT: integrating routine use with theranostics growth. Attendees then heard guest speaker Kirsten Korsholm, MD, PhD, nuclear medicine physician from Rigshospitalet, Copenhagen, Denmark, deliver remarks on first experiences with BIOGRAPH One PET/MR and on their work with Biograph Vision Quadra long axial field-of-view (LAFOV) PET/CT.

Accelerating the momentum

The 2025 SNMMI Annual Meeting successfully accelerated the momentum for discovery and collaboration in nuclear medicine and molecular imaging. The next annual meeting will take place on May 31, 2026, in Los Angeles, California, USA. ●

Biograph Trinion, Biograph Vision Quadra, and Symbia Pro.specta are not commercially available in all countries. Future availability cannot be guaranteed.

* BIOGRAPH One is currently under development and not commercially available. It's not for sale in the United States. Its future availability cannot be ensured.

The statements by Siemens Healthineers customers described herein are based on results that were achieved in the customer's unique setting. Because there is no “typical” hospital or laboratory and many variables exist (e.g., hospital size, samples mix, case mix, level of IT, and/or automation adoption) there can be no guarantee that other customers will achieve the same results.

For More Information

[siemens-healthineers.com/snmml](https://www.siemens-healthineers.com/snmml)

[siemens-healthineers.com/clinical-specialities/theranostics](https://www.siemens-healthineers.com/clinical-specialities/theranostics)

[siemens-healthineers.com/en-us/molecular-imaging/petnet](https://www.siemens-healthineers.com/en-us/molecular-imaging/petnet)

[siemens-healthineers.com/prospecta](https://www.siemens-healthineers.com/prospecta)

[siemens-healthineers.com/quadra](https://www.siemens-healthineers.com/quadra)

Reference

- <https://snmmi.org/Web/News/Articles/SNMMI-Image-of-the-Year--New-Immuno-PET-Tracer-Superior-to-FDG-PET-in-Predicting-PD-L1-Expression-in.Mobile.aspx>